Nervous system

Nuvoton Unveils New Production-Ready Endpoint AI Platform for Machine Learning

Retrieved on: 
Friday, January 5, 2024

HSINCHU, Jan. 5, 2024 /PRNewswire/ -- Nuvoton is pleased to announce its new Endpoint AI Platform to accelerate the development of fully-featured microcontroller (MCU) AI products. These solutions are enabled by Nuvoton's powerful new MCU and MPU silicon, including the NuMicro® M55M1 equipped with Ethos U55 NPU, NuMicro® MA35D1, and NuMicro® M467 series. These MCUs are a valuable addition to the modern AI-centric computing toolkit and demonstrate how Nuvoton continues to work closely with Arm and other companies to develop a user-friendly and complete Endpoint AI Ecosystem.

Key Points: 
  • HSINCHU, Jan. 5, 2024 /PRNewswire/ -- Nuvoton is pleased to announce its new Endpoint AI Platform to accelerate the development of fully-featured microcontroller (MCU) AI products.
  • Development on these platforms is made easy by Nuvoton's NuEdgeWise: a well-rounded, simple-to-adopt tool for machine learning (ML) development, which is nonetheless suitable for cutting-edge tasks.
  • Together, this powerful core hardware, combined with unique rich development tools, cements Nuvoton's reputation as a leading microcontroller platform provider.
  • NuEdgeWise leverages the popular Jupyter Notebook platform, allowing developers to train and deploy models on Nuvoton chips using TensorFlow Lite.

Autonomix Medical, Inc. Provides Business Overview and Highlights Upcoming Milestones

Retrieved on: 
Thursday, January 4, 2024

THE WOODLANDS, TX, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (“Autonomix” or the “Company”) a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today provided a business overview and highlighted upcoming milestones.

Key Points: 
  • THE WOODLANDS, TX, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (“Autonomix” or the “Company”) a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today provided a business overview and highlighted upcoming milestones.
  • Lori Bisson, Chief Executive Officer of Autonomix, commented, “Autonomix is dedicated to dramatically improving the quality of millions of lives by empowering the nerve-directed treatments of tomorrow.
  • Achieving “proof-of-concept” in this area could open the door to blockbuster diseases, expanding the horizons for the Company’s technology.
  • The smaller and shorter clinical trials potentially translate to more efficient resource utilization, minimizing overall development costs.

Human medicines European public assessment report (EPAR): Blincyto, blinatumomab, Date of authorisation: 23/11/2015, Revision: 19, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Blincyto, blinatumomab, Date of authorisation: 23/11/2015, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Blincyto, blinatumomab, Date of authorisation: 23/11/2015, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Vimpat, lacosamide, Date of authorisation: 29/08/2008, Revision: 47, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Vimpat, lacosamide, Date of authorisation: 29/08/2008, Revision: 47, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Vimpat, lacosamide, Date of authorisation: 29/08/2008, Revision: 47, Status: Authorised

Human medicines European public assessment report (EPAR): Briumvi, ublituximab, Date of authorisation: 31/05/2023, Revision: 2, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Briumvi, ublituximab, Date of authorisation: 31/05/2023, Revision: 2, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Briumvi, ublituximab, Date of authorisation: 31/05/2023, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 42, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 42, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 42, Status: Authorised

Young people took up smoking during the pandemic – how tobacco has been used for stress relief for more than a century

Retrieved on: 
Saturday, December 30, 2023

But during some of the most anxiety-ridden months of the COVID pandemic in early 2020, that rate of decline slowed almost to a stop.

Key Points: 
  • But during some of the most anxiety-ridden months of the COVID pandemic in early 2020, that rate of decline slowed almost to a stop.
  • A recent study suggests that the social disruption, boredom and stress brought about by the pandemic may have contributed to a rise in young people taking up smoking.

Smoking as stress relief

  • For some, it was the drug of modernity, as its soothing effects (caused by nicotine) were the ideal antidote to the stress and tension that came with the machine age.
  • The invention of new technology such as the telegraph and railways made life more fast-paced and stressful.
  • At the turn of the 20th century, even medical journal The Lancet suggested that smoking could ease the “restlessness and irritability” that accompanied urban life.
  • In earlier conflicts, including the Boer war (1899-1902) and the Crimean war (1853-56), many military and medical writers had said much the same thing.
  • But the machine-made cigarette made smoking more accessible.

Concerns about young smokers

  • As I’ve found when reading journals from the early 1900s at the British Library, smoking was seen by some doctors and anti-tobacco activists to cause bad manners and antisocial behaviour in idle young boys.
  • Smoking was endangering the health of the next generation and, by extension, the health and longevity of the British empire.
  • Much like the young soldiers who had to endure a mix of intense stress and numbing boredom in the major wars of the modern era, the new, youthful smokers of the pandemic perhaps lit their first ever cigarette to deal with life in lockdown.


Michael Reeve does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Autonomix Medical, Inc. to Participate in the Virtual Investor Fireside Chat

Retrieved on: 
Thursday, December 14, 2023

THE WOODLANDS, TX, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (“Autonomix” or the “Company”) a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Lori Bisson, Chief Executive Officer of Autonomix, will participate in the Virtual Investor Fireside Chat featuring Autonomix on Tuesday, December 19, 2023 at 3:00 PM ET.

Key Points: 
  • As part of the event, management will discuss the Company’s innovative technologies in development to revolutionize how diseases involving the peripheral nervous system are diagnosed and treated.
  • In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event.
  • A live video webcast of the fireside chat will be available on the Events page of the Company’s website ( autonomix.com ).
  • A webcast replay will be available two hours following the live event and will be accessible for 90 days.

Canada’s National Farm Leadership Program Now Accepting Applications

Retrieved on: 
Monday, December 11, 2023

Canada already has some of the best farm managers and increasing their leadership effectiveness is the next step.

Key Points: 
  • Canada already has some of the best farm managers and increasing their leadership effectiveness is the next step.
  • The National Farm Leadership Program teaches you how to perform at your best when it matters most.
  • The next cohort of the National Farm Leadership Program will begin its journey on January 29, 2024.
  • The deadline to apply to the National Farm Leadership Program is January 18th.